AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22848033 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoterate (0.1 mmol/kg)
Number of subjects: 20
Study 22848033 — intervention group
Group type: COMPARATOR
Intervention: Gadobutrol (0.1 mmol/kg)
Number of subjects: 20
Study 22848033 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 20
Study 22848033 — intervention group
Group type: COMPARATOR
Intervention: Gadoterate
Number of subjects: 20
Study 20234301 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB plus azelnidipine (AZ group)
Number of subjects: 37
Study 20234301 — intervention group
Group type: COMPARATOR
Intervention: ARB plus trichlormethiazide (TCM group)
Number of subjects: 37
Study 19029270 — intervention group
Group type: EXPERIMENTAL
Intervention: 40,000 IU of epoetin alpha (EPOalpha)
Number of subjects: 67
Study 19029270 — intervention group
Group type: COMPARATOR
Intervention: Standard medical and surgical treatment
Number of subjects: 67
Study 15836934 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation exercises (S&G group)
Number of subjects: 55
Study 15836934 — intervention group
Group type: COMPARATOR
Intervention: General exercise only (G group)
Number of subjects: 55
Study 12207568 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/day
Number of subjects: 0
Study 12207568 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 40 mg/day
Number of subjects: 0
Study 12207568 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/day in hypercholesterolaemic patients
Number of subjects: 0
Study 12207568 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 40 mg/day in hypercholesterolaemic patients
Number of subjects: 0
Study 12207568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12207568 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (20 and 40 mg/day)
Number of subjects: 0
Study 11235577 — intervention group
Group type: EXPERIMENTAL
Intervention: Zeng Sheng-ping (ZSP), 8 tablets, twice a day for 6 months
Number of subjects: 449
Study 11235577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 11235577 — intervention group
Group type: EXPERIMENTAL
Intervention: Zeng Sheng-ping (ZSP)
Number of subjects: 449
Study 8670315 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric anti-TNF alpha antibody cA2 (1 or 10 mg/kg)
Number of subjects: 0
Study 8670315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8670315 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric anti-TNF alpha antibody cA2
Number of subjects: 0
Study 1984989 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol 270 micrograms (three puffs) from a metered dose inhaler
Number of subjects: 18
Study 1984989 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 2.5 mg from a saline solution nebulized with an updraft inhaler
Number of subjects: 18
Study 1984989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both delivery methods
Number of subjects: 18
Study 6135076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD)
Number of subjects: 30
Study 6135076 — intervention group
Group type: COMPARATOR
Intervention: Volume repletion
Number of subjects: 30
Study 31492475 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 720
Study 31492475 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 720
Study 28905830 — intervention group
Group type: EXPERIMENTAL
Intervention: Recession and resection (R&R)
Number of subjects: 40
Study 28905830 — intervention group
Group type: COMPARATOR
Intervention: Recession and plication (R&P)
Number of subjects: 40
Study 26076204 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic group psychotherapy (LTG)
Number of subjects: 0
Study 26076204 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychodynamic group psychotherapy (STG)
Number of subjects: 0
Study 24451697 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled 1600 μg salbutamol
Number of subjects: 16
Study 24451697 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 16
Study 22130425 — intervention group
Group type: COMPARATOR
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 30
Study 22130425 — intervention group
Group type: COMPARATOR
Intervention: Sublingual Immunotherapy followed by Oral Immunotherapy (SLIT/OITB)
Number of subjects: 30
Study 22130425 — intervention group
Group type: COMPARATOR
Intervention: Oral Immunotherapy (OITA)
Number of subjects: 30
Study 22130425 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OITB)
Number of subjects: 30
Study 22130425 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reaction rate
Number of subjects: 30
Study 22130425 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated CM skin prick test results
Number of subjects: 30
Study 22130425 — intervention group
Group type: EXPERIMENTAL
Intervention: CD63 and CD203c expression
Number of subjects: 30
Study 22130425 — intervention group
Group type: EXPERIMENTAL
Intervention: CM-specific IgG(4) levels
Number of subjects: 30
Study 22130425 — intervention group
Group type: EXPERIMENTAL
Intervention: CM-specific IgE and spontaneous histamine release values
Number of subjects: 30
Study 20223648 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 0
Study 20223648 — intervention group
Group type: COMPARATOR
Intervention: 0.0625% bupivacaine
Number of subjects: 0
Study 17646413 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole 200 mg BID for 3 days, followed by ritonavir 400 mg BID for 10 days, then voriconazole 200 mg BID with ritonavir for 10 days (Study A)
Number of subjects: 51
Study 17646413 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole 200 mg BID for 3 days, followed by ritonavir 100 mg BID for 10 days, then voriconazole 200 mg BID with ritonavir for 10 days (Study B)
Number of subjects: 51
Study 17646413 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole coadministered with high-dose ritonavir
Number of subjects: 51
Study 17646413 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole coadministered with low-dose ritonavir
Number of subjects: 51
Study 17646413 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy of voriconazole and ritonavir
Number of subjects: 51
Study 15094733 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% added to timolol maleate 0.5%
Number of subjects: 33
Study 15094733 — intervention group
Group type: COMPARATOR
Intervention: Unoprostone 0.15% added to timolol maleate 0.5%
Number of subjects: 33
Study 15094733 — intervention group
Group type: COMPARATOR
Intervention: Unoprostone 0.15%
Number of subjects: 33
Study 12409716 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy with cyproterone acetate (CPA), 300 mg/day for 12 weeks
Number of subjects: 192
Study 12409716 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy with cyproterone acetate (CPA)
Number of subjects: 192
Study 12409716 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control)
Number of subjects: 192
Study 9793616 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard, slow-release horse chestnut seed extract (HCSE)
Number of subjects: 0
Study 9793616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-release test preparation (Noricaven novo)
Number of subjects: 0
Study 9793616 — intervention group
Group type: COMPARATOR
Intervention: Both products (HCSE and Noricaven novo)
Number of subjects: 0
Study 7633141 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 or NaCl (2 mmol/kg/day each) for 7 days
Number of subjects: 149
Study 7633141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific therapy)
Number of subjects: 149
Study 3720570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (10,000 men) received dietary advice, smoking cessation advice, and antihypertensive treatment.
Number of subjects: 30000
Study 3720570 — intervention group
Group type: COMPARATOR
Intervention: Control group (20,000 men) received health examinations and general health advice.
Number of subjects: 30000
Study 31711275 — intervention group
Group type: EXPERIMENTAL
Intervention: e-health self-control training during inpatient MOT (intensive phase)
Number of subjects: 68
Study 31711275 — intervention group
Group type: EXPERIMENTAL
Intervention: e-health self-control training during outpatient aftercare (booster phase)
Number of subjects: 68
Study 31711275 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adherence group
Number of subjects: 68
Study 31711275 — intervention group
Group type: EXPERIMENTAL
Intervention: End of inpatient MOT and high weight status
Number of subjects: 68
Study 29482683 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine plus Ketac Molar
Number of subjects: 30
Study 29482683 — intervention group
Group type: EXPERIMENTAL
Intervention: NuSmile NeoMTA plus Tempit LC
Number of subjects: 30
Study 29482683 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoMTA Plus plus Fuji IX
Number of subjects: 30
Study 29482683 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Angelus plus IRM capsule
Number of subjects: 30
Study 29482683 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Flow plus IRM powder and liquid
Number of subjects: 30
Study 29482683 — intervention group
Group type: EXPERIMENTAL
Intervention: Solo bioactive cement pulp chamber filling (protocol B)
Number of subjects: 30
Study 29482683 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 30
Study 27439408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 60
Study 27439408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 60
Study 24667518 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal mentoring curriculum
Number of subjects: 16
Study 22615152 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial capsule reefing (Group A)
Number of subjects: 78
Study 22615152 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial patellar retinaculum plasty (Group B)
Number of subjects: 78
Study 20227675 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser flap creation
Number of subjects: 21
Study 20227675 — intervention group
Group type: COMPARATOR
Intervention: Mechanical microkeratome flap creation
Number of subjects: 21
Study 20227675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 21
Study 18164457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal electrothermal therapy
Number of subjects: 0
Study 19931756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 110
Study 19931756 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic lactate saline (HLS) solution
Number of subjects: 110
Study 15675479 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose mitomycin and epirubicin with caval chemofiltration (CF)
Number of subjects: 42
Study 15675479 — intervention group
Group type: COMPARATOR
Intervention: Low doses of mitomycin and epirubicin
Number of subjects: 42
Study 11372943 — intervention group
Group type: EXPERIMENTAL
Intervention: Medoff sliding plate (MSP)
Number of subjects: 569
Study 11372943 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 569
Study 11372943 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw with trochanteric stabilizing plate (DHS/TSP)
Number of subjects: 569
Study 11372943 — intervention group
Group type: COMPARATOR
Intervention: Dynamic condylar screw (DCS)
Number of subjects: 569
Study 11372943 — intervention group
Group type: COMPARATOR
Intervention: All groups (MSP vs DHS, DHS/TSP, DCS)
Number of subjects: 569
Study 11372943 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP
Number of subjects: 569
Study 11372943 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 569
Study 9248749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 3 mg/kg i.v. bolus and norfloxacin 400 mg twice daily orally from the start
Number of subjects: 158
Study 9248749 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 2 g i.v. twice daily for at least two days followed by norfloxacin 400 mg twice daily orally
Number of subjects: 158
Study 9248749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 158
Study 9248749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin with early oral therapy
Number of subjects: 158
Study 8321793 — intervention group
Group type: EXPERIMENTAL
Intervention: Imprint cytology
Number of subjects: 239
Study 8321793 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 239
Study 8321793 — intervention group
Group type: COMPARATOR
Intervention: CLO-test
Number of subjects: 239
Study 8321793 — intervention group
Group type: COMPARATOR
Intervention: CLO-test in patients receiving colloidal bismuth subcitrate
Number of subjects: 239
Study 3541564 — intervention group
Group type: EXPERIMENTAL
Intervention: Manufactured snacks (chocolate‐coated candy bar; cola drink with crisps)
Number of subjects: 10
Study 3541564 — intervention group
Group type: COMPARATOR
Intervention: Whole-food snacks (raisins and peanuts; bananas and peanuts)
Number of subjects: 10
Study 3541564 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana-peanut snack
Number of subjects: 10
Study 3541564 — intervention group
Group type: EXPERIMENTAL
Intervention: Manufactured snacks
Number of subjects: 10
Study 3541564 — intervention group
Group type: COMPARATOR
Intervention: Whole-food snacks
Number of subjects: 10
Study 4593555 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (aspirin) - single daily dose
Number of subjects: 1239
Study 30773798 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 3555
Study 30773798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3555
Study 30166087 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sarcoidosis and IPF (CSIPF)
Number of subjects: 78
Study 30166087 — intervention group
Group type: COMPARATOR
Intervention: Lone-IPF
Number of subjects: 78
Study 30166087 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary sarcoidosis
Number of subjects: 78
Study 26833624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray for 14 days
Number of subjects: 80
Study 22886317 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-organizational collaboration
Number of subjects: 38
Study 22886317 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care
Number of subjects: 38
Study 22265994 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR 30 mg intramuscular on days 1, 29, and 57, plus daily immediate-release octreotide 600 μg per day and methylprednisolone on days 1 to 6.
Number of subjects: 64
Study 22265994 — intervention group
Group type: COMPARATOR
Intervention: Placebo with methylprednisolone instead of octreotide.
Number of subjects: 64
Study 22265994 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR in patients with baseline Karnofsky score >= 50.
Number of subjects: 64
Study 22265994 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with baseline Karnofsky score >= 50.
Number of subjects: 64
Study 21069110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid composite (Filtek Z100 Universal Restorative)
Number of subjects: 90
Study 21069110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocomposite (Filtek Z350)
Number of subjects: 90
Study 21069110 — intervention group
Group type: COMPARATOR
Intervention: Ormocer (Voco Admira)
Number of subjects: 90
Study 18210355 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED) for lumbar disc herniation with bony fragment
Number of subjects: 18
Study 18210355 — intervention group
Group type: COMPARATOR
Intervention: Microendoscopic discectomy (MED) for lumbar disc herniation without bony fragment (Control group)
Number of subjects: 18
Study 15336334 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 187
Study 15336334 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 187
Study 11673215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal-mask NPPV
Number of subjects: 48
Study 11673215 — intervention group
Group type: COMPARATOR
Intervention: No-NPPV
Number of subjects: 48
Study 9843006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% shampoo (3-day application)
Number of subjects: 312
Study 9843006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% shampoo (1-day application)
Number of subjects: 312
Study 9843006 — intervention group
Group type: COMPARATOR
Intervention: Placebo shampoo
Number of subjects: 312
Study 7735003 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling with stages-of-change model
Number of subjects: 93
Study 7735003 — intervention group
Group type: COMPARATOR
Intervention: Reminder reading 'Ask your patients to stop smoking'
Number of subjects: 93
Study 7735003 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 93
Study 2785982 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech processor with electrical stimulation
Number of subjects: 38
Study 2785982 — intervention group
Group type: EXPERIMENTAL
Intervention: Processor delivering subthreshold current for 2 weeks
Number of subjects: 38
Study 2785982 — intervention group
Group type: COMPARATOR
Intervention: Placebo trial
Number of subjects: 38
Study 29567399 — intervention group
Group type: COMPARATOR
Intervention: BI 409306 25 mg, 50 mg, 100 mg, placebo once daily (OD) for 14 days (Trial 1)
Number of subjects: 0
Study 29567399 — intervention group
Group type: COMPARATOR
Intervention: BI 409306 25 mg, 50 mg, placebo OD for 14 days (Trial 2)
Number of subjects: 0
Study 29567399 — intervention group
Group type: COMPARATOR
Intervention: BI 409306 25 mg, 50 mg, 100 mg, placebo single doses (SD) (Trial 3)
Number of subjects: 0
Study 29567399 — intervention group
Group type: COMPARATOR
Intervention: BI 409306 100 mg SD or placebo for Chinese poor metabolisers (PM) (Trial 3)
Number of subjects: 0
Study 29567399 — intervention group
Group type: COMPARATOR
Intervention: BI 409306 100 mg OD for 7 days after a 48-hour washout period (Japanese PM, Trial 3)
Number of subjects: 0
Study 29567399 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 (various doses)
Number of subjects: 0
Study 28778393 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.4 g of fish oil
Number of subjects: 80
Study 26297574 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol 0.05% ointment applied daily for 14 days
Number of subjects: 15
Study 26297574 — intervention group
Group type: COMPARATOR
Intervention: Control petrolatum ointment applied daily for 14 days
Number of subjects: 15
Study 26297574 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol 0.05% ointment
Number of subjects: 15
Study 26297574 — intervention group
Group type: COMPARATOR
Intervention: Control petrolatum ointment
Number of subjects: 15
Study 22781309 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (60% VO2max)
Number of subjects: 35
Study 22781309 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (80% VO2max)
Number of subjects: 35
Study 21635612 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockade during exercise
Number of subjects: 10
Study 21635612 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockade during recovery
Number of subjects: 10
Study 21635612 — intervention group
Group type: COMPARATOR
Intervention: β-blockade during exercise in normal subjects
Number of subjects: 10
Study 21635612 — intervention group
Group type: COMPARATOR
Intervention: β-blockade during recovery in normal subjects
Number of subjects: 10
Study 18439469 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal nasal dilation stent (INDS)
Number of subjects: 23
Study 18439469 — intervention group
Group type: COMPARATOR
Intervention: External nasal dilator (END)
Number of subjects: 23
Study 16542392 — intervention group
Group type: EXPERIMENTAL
Intervention: Common genetic variants of HDL-C-related genes
Number of subjects: 546
Study 16542392 — intervention group
Group type: EXPERIMENTAL
Intervention: Common genetic variants of HDL-C-related genes with covariates smoking and body mass index
Number of subjects: 546
Study 16542392 — intervention group
Group type: EXPERIMENTAL
Intervention: Common genetic variants of HDL-C-related genes with covariates and 10 two-way interactions
Number of subjects: 546
Study 12022154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 500 mg for 3 days
Number of subjects: 43
Study 12022154 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 43
Study 11910595 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg daily) for 8 weeks
Number of subjects: 23
Study 11910595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone therapy (up to 1.25 mg of conjugated equine estrogens plus 5 mg of medroxyprogesterone acetate daily) for 8 weeks
Number of subjects: 23
Study 11910595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of simvastatin and hormone therapy (same dosages as above)
Number of subjects: 23
Study 8944104 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing (intervention)
Number of subjects: 95
Study 8944104 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous resolution (control)
Number of subjects: 95
Study 8944104 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing at 12-14 months (intervention)
Number of subjects: 95
Study 1783919 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-Diaminopyridine (3,4-DAP)
Number of subjects: 16
Study 1783919 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-Diaminopyridine (3,4-DAP) in a double blind crossover trial
Number of subjects: 16
Study 6814669 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic analogue of enkephalin
Number of subjects: 5
Study 6814669 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.5 ml)
Number of subjects: 5
Study 6814669 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg IV)
Number of subjects: 5
Study 31303007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive Movement Reembodiment (IMR) program, 10 weekly sessions
Number of subjects: 22
Study 31411779 — intervention group
Group type: COMPARATOR
Intervention: Randomised treatment
Number of subjects: 0
Study 31411779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediator levels
Number of subjects: 0